BofA raised the firm’s price target on Johnson & Johnson to $175 from $161 and keeps a Neutral rating on the shares. The firm’s target is still based on a sum-of-the-parts valuation, but now using its new 2026 EPS estimates, the analyst tells investors after J&J reported a Q2 EPS beat and raised 2025 guidance.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JNJ:
- Johnson & Johnson price target raised to $172 from $159 at Bernstein
- Johnson & Johnson price target raised to $176 from $165 at Barclays
- Johnson & Johnson Stock (JNJ) Gets a Price Target Boost by Stifel’s Analyst Post Q2 Earnings Beat
- Johnson & Johnson Reports Strong Quarterly Growth
- Johnson & Johnson: Strong Performance Overshadowed by Biosimilar Competition and Litigation Risks